

EMA/257780/2020

European Medicines Agency decision

P/0221/2020

of 17 June 2020

on the acceptance of a modification of an agreed paediatric investigation plan for lucerastat (EMA-002095-PIP01-16-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0221/2020

of 17 June 2020

on the acceptance of a modification of an agreed paediatric investigation plan for lucerastat (EMA-002095-PIP01-16-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0034/2018 issued on 30 January 2018,

Having regard to the application submitted by Idorsia Pharmaceuticals Deutschland GmbH on 23 January 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 30 April 2020, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for lucerastat, capsule, hard, age-appropriate oral solid paediatric formulation, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Idorsia Pharmaceuticals Deutschland GmbH, Marie-Curie-Strasse 8, 79539 – Lörrach, Germany.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/70354/2020
Amsterdam, 30 April 2020

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002095-PIP01-16-M01

Scope of the application

Active substance(s):

Lucerastat

Condition(s):

Treatment of Fabry disease

Pharmaceutical form(s):

Capsule, hard

Age-appropriate oral solid paediatric formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Idorsia Pharmaceuticals Deutschland GmbH

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Idorsia Pharmaceuticals Deutschland GmbH submitted to the European Medicines Agency on 23 January 2020 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0034/2018 issued on 30 January 2018.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 2 March 2020.



Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of Fabry disease

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- capsule, hard, age-appropriate oral solid paediatric formulation, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition

Treatment of Fabry disease

2.1.1. Indication(s) targeted by the PIP

Treatment of Fabry disease

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

Age-appropriate oral solid paediatric formulation

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an age-appropriate oral solid paediatric formulation.
Non-clinical studies	2	Study 2 Preliminary dose-range finding juvenile toxicity study in rats. Study 3 Definitive juvenile toxicity study in rats.

Clinical studies	1	Study 4 (ID-069A303) Open-label, prospective, multicentre, single-arm study to evaluate pharmacokinetics, safety, tolerability and explore the clinical activity of lucerastat in paediatric patients with Fabry disease.
Extrapolation, modelling and simulation studies	1	Study 5 Extrapolation study, to support the efficacy and safety assumptions in the paediatric population based on similar exposure compared to the adult population.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes